Learning from PD-1 Resistance: New Combination Strategies
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Only a minority of cancer patients respond to anti PD-1 immunotherapy. A recent study demonstrates that PD-1 therapy-resistant melanoma patients present distinct signatures of upregulated genes involved in immunosuppression, angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix remodeling, and epithelial-mesenchymal transition (EMT). Combination-targeting of these pathways with PD-1 may help overcome PD-1 resistance, thus producing effective antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“analyzed the genomic and transcriptomic features of pretreatment tumor specimens to determine molecular signatures distinguishing response from resistance in metastatic melanoma patients treated with PD-1 blockade immunotherapy [1].”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 12×
“As illustrated in Figure 1, the IPRES signature includes genes involved in immunosuppression (IL10) and angiogenesis (VEGFA, VEGFC, FLT1, and ANGPT2), monocyte and macrophage chemotaxis (CCL2, CCL7, CCL8, CCL13) and epithelial-mesenchymal transition (EMT) (AXL, ROR2, WNT5A, LOXL2, TWIST2, TAGLN, FAP).”
BackgroundInfluentialKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Self-citationEbert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · cited 1×
“While MEK inhibition blocked in vivo priming of murine naïve T cells, it potentiated previously activated antitumor T cells by impairing TCRdriven apoptosis [10].”
Background
Cited by
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Mechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
Liu, C., Chikina, M., Deshpande, R., Menk, A. V., Wang, T., Tabib, T., Brunazzi, E. A., Vignali, K. M., Sun, M., Stolz, D. B., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.017 · Cited by 345
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles
Wei, Z., Zhang, X., Yong, T., Bie, N., Zhan, G., Li, X., Liang, Q., Li, J., Yu, J., Huang, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20723-x · Cited by 342
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05992-x · Cited by 313
Metadata
- Authors
- Bu, X., Mahoney, K. M., & Freeman, G. J.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 22
- Issue
- 6
- Pages
- 448-451
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2346535379
- Cited by
- 71
- References
- 4
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Learning from PD-1 Resistance: New Combination Strategies. https://app.cochat.ai/papers/10.1016/j.molmed.2016.04.008
- The paper
- Bu, X., Mahoney, K. M., & Freeman, G. J. (2016). Learning from PD-1 Resistance: New Combination Strategies. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2016.04.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.